Number of shares and votes in Medivir

Number of shares and votes in Medivir

The number of shares and votes in Medivir has changed as a result of the
exercise of employee stock options.

Today, the last trading day of the month, there are in total 31,244,606
shares and 37,184,606 votes in the company.
 

For further information, please contact:
Rein Piir, CFO and VP, Investor Relations, -468708-537 292
 

About Medivir
Medivir is an emerging research-based specialty pharmaceutical company
focused on the development of high-value treatments for infectious
diseases. Medivir has world class expertise in polymerase and protease
drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company's key pipeline asset is
TMC435, a novel protease inhibitor is in phase 3 clinical development
for hepatitis C and is partnered with Tibotec Pharmaceuticals. In June
2011, Medivir acquired the specialty pharmaceutical company BioPhausia
to ensure timely commercialization of TMC435 in the Nordic markets, once
approved.

Medivir's first product, the unique cold sore product Xerese™/Xerclear®
was launched on the US market in February 2011. Xerese™/Xerclear®, which
has been approved in both the US and Europe is partnered with
GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in
North America, Canada and Mexico have recently been sold to Meda AB.
Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information about Medivir, please visit the Company's website:
www.medivir.com (http://www.medivir.com/).